Medical 21
Plymouth, US · Founded 2016 · Minnesota corporation
Medical 21 develops the MAVERICS Graft, a synthetic regenerative vascular graft that lets surgeons perform complete cardiac bypass procedures without harvesting the patient's own blood vessels. The graft uses a nitinol scaffold and stimulates angiogenesis so the body forms an arterial-like vessel from the patient's own cells, targeting coronary bypass surgery.
Founders & leadership
Medical 21 was founded in 2016 by Manny Villafaña.
MV
Manny VillafañaCEO
ES
Eric SolienExecutive
EH
Erik HermansenExecutive
CS
Chaid SchwarzExecutive
JV
Jeff VreemanExecutive
AS
Andrea SweeneyExecutive
Reported raises · per SEC filings
Form D private placements$16.7M disclosed across 6 of 7 rounds · 2016–2024
▶$10MraisedAug 2025 · 39 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2025 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric SolienExecutive Officer
- Erik HermansenExecutive Officer
- Chaid SchwarzExecutive Officer
- Manny VillafanaExecutive Officer, Director, Promoter
- Jeff VreemanExecutive Officer
- Andrea SweeneyExecutive Officer
- Offering amount
- $20M
- Amount sold
- $10M
- Proceeds to insiders
- $500K
- First sale
- Feb 2023
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$2.5MraisedSep 2022 · 1 investors · BiotechnologyRule 506(c)
▶$2.5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Manny VillafanaExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $2.5M
- Minimum investment
- $2.5M
- Proceeds to insiders
- $500K
- First sale
- Sep 2022
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06c
▶$3MraisedJan 2021 · 15 investors · BiotechnologyRule 506(b)
▶$3MraisedJan 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manny VillafanaExecutive Officer, Director, Promoter
- Offering amount
- $10M
- Amount sold
- $3M
- Proceeds to insiders
- $500K
- First sale
- Feb 2019
- Incorporated
- Corporation, Minnesota, 2016
- Federal exemptions
- 06b
▶$750KraisedAug 2018 · 5 investors · BiotechnologyRule 506(b)
▶$750KraisedAug 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric SolienExecutive Officer
- Manny VillafanaExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $750K
- Proceeds to insiders
- $500K
- First sale
- Dec 2017
- Incorporated
- Corporation, Minnesota, 2016
- Federal exemptions
- 06b
▶$250KraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric SolienExecutive Officer
- Manny VillafanaExecutive Officer, Director, Promoter
- Offering amount
- $15M
- Amount sold
- $250K
- Proceeds to insiders
- $500K
- First sale
- Aug 2017
- Incorporated
- Corporation, Minnesota, 2016
- Federal exemptions
- 06b
▶$200KraisedMay 2016 · 2 investors · ManufacturingRule 506(b)
▶$200KraisedMay 2016 · 2 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- Manny VillafanaExecutive Officer, Director, Promoter
- Offering amount
- $2M
- Amount sold
- $200K
- First sale
- Apr 2016
- Incorporated
- Corporation, Minnesota, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Doximity4 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Title21 Health Solutions4 shared keywordsTitle21 provides software solutions for cellular therapy and biopharmaceutical manufacturing organizations, offering digital tools for patient coordination, manufacturing workflows, quality management, and regulatory compliance.
Companies competing with Medical 21 for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Medical 21 do?
- Medical 21 develops the MAVERICS Graft, a synthetic regenerative vascular graft that lets surgeons perform complete cardiac bypass procedures without harvesting the patient's own blood vessels. The graft uses a nitinol scaffold and stimulates angiogenesis so the body forms an arterial-like vessel from the patient's own cells, targeting coronary bypass surgery.
- Who founded Medical 21?
- Medical 21 was founded by Manny Villafaña in 2016.
- How much funding has Medical 21 raised?
- Medical 21 has disclosed $16.7M raised across 6 of its 7 known rounds.
- Where is Medical 21 headquartered?
- Medical 21 is headquartered in Plymouth, US.